

# FDG PET/CT Pitfalls in Gynecologic and Genitourinary Cancers

Radiographics

37, 577-594

DOI: 10.1148/rg.2017160059

Citation Report

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 579-594.  | 4.6  | 22        |
| 2  | What's New in Imaging for Gynecologic Cancer?. <i>Current Oncology Reports</i> , 2017, 19, 85.   | 4.0  | 15        |
| 3  | Pilot study utilizing Fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography for glycolytic phenotyping of canine mast cell tumors. <i>Veterinary Radiology and Ultrasound</i> , 2018, 59, 461-468.   | 0.9  | 11        |
| 4  | PET/CT in Oncologic Imaging of Nodal Disease: Pearls and Pitfalls: <i>RadioGraphics Fundamentals   Online Presentation</i>. <i>Radiographics</i> , 2018, 38, 564-565.  | 3.3  | 4         |
| 5  | Current and Future Use of Radiological Images in the Management of Gynecological Malignancies – A Survey of Practice in the UK. <i>Anticancer Research</i> , 2018, 38, 5867-5876.  | 1.1  | 1         |
| 6  | A glance at imaging bladder cancer. <i>Clinical and Translational Imaging</i> , 2018, 6, 257-269.  | 2.1  | 11        |
| 7  | Clinical Value of 18 F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer. <i>Clinical Oncology</i> , 2018, 30, 507-514. | 1.4  | 10        |
| 8  | FDG-PET Imaging in Cervical Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 461-470.   | 4.6  | 29        |
| 9  | Combinative evaluation of primary tumor and lymph nodes in predicting pelvic lymphatic metastasis in early-stage cervical cancer: A multiparametric PET-CT study. <i>European Journal of Radiology</i> , 2019, 113, 153-157.   | 2.6  | 18        |
| 10 | Aberrant Hypermetabolism of Benign Uterine Leiomyoma on 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e413-e414.  | 1.3  | 10        |
| 11 | The Role of Positron Emission Tomography/Magnetic Resonance Imaging in Gynecological Malignancies. <i>Journal of Computer Assisted Tomography</i> , 2019, 43, 825-834.   | 0.9  | 6         |
| 12 | FDG-PET/CT for Detecting an Infection Focus in Patients With Bloodstream Infection. <i>Clinical Nuclear Medicine</i> , 2019, 44, 99-106.   | 1.3  | 26        |
| 14 | Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT. <i>Medicine (United States)</i> , 2020, 99, e22417.   | 1.0  | 2         |
| 15 | Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma – a literature review. <i>Abdominal Radiology</i> , 2021, 46, 2323-2349.  | 2.1  | 16        |
| 16 | 2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging. <i>Radiographics</i> , 2020, 40, 1807-1822.   | 3.3  | 40        |
| 17 | Relationship between Standard Uptake Values of Positron Emission Tomography/Computed Tomography and Salivary Metabolites in Oral Cancer: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3958.                   | 2.4  | 11        |
| 18 | Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies. <i>Nature Communications</i> , 2020, 11, 1364.                      | 12.8 | 23        |
| 19 | PET/MRI Characterization of Mucinous Versus Nonmucinous Components of Rectal Adenocarcinoma: A Comparison of Tumor Metabolism and Cellularity. <i>American Journal of Roentgenology</i> , 2021, 216, 376-383.                  | 2.2  | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 20 | FDG PET/CT in Treatment Response Evaluation of Gynecological Malignancies. , 2021, , 297-332.   |     | 0         |
| 21 | <sup>18</sup> F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Postsurgical and Postprocedural Setting in Thorax and Abdominopelvic Malignancies: A Pictorial Essay (Part II). Indian Journal of Nuclear Medicine, 2021, 36, 319.       | 0.3 | 0         |
| 22 | CT-less Direct Correction of Attenuation and Scatter in the Image Space Using Deep Learning for Whole-Body FDG PET: Potential Benefits and Pitfalls. Radiology: Artificial Intelligence, 2021, 3, e200137.  | 5.8 | 28        |
| 23 | Uterine leiomyomas revisited with review of literature. Abdominal Radiology, 2021, 46, 4908-4926.   | 2.1 | 9         |
| 24 | 68Ga-FAPI-PET/CT in patients with various gynecological malignancies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4089-4100.  | 6.4 | 91        |
| 25 | FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. Seminars in Nuclear Medicine, 2021, 51, 554-571.   | 4.6 | 9         |
| 26 | PET/CT Variants and Pitfalls in Gynecological Cancers. Seminars in Nuclear Medicine, 2021, 51, 593-610.   | 4.6 | 17        |
| 27 | Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation. Seminars in Nuclear Medicine, 2021, 51, 633-645.  | 4.6 | 58        |
| 28 | PET/CT Limitations and Pitfalls in Urogenital Cancers. Seminars in Nuclear Medicine, 2021, 51, 611-620.   | 4.6 | 7         |
| 29 | PET/CT and PET/MRI, Normal Variations, and Artifacts. , 2020, , 549-584.  |     | 2         |
| 30 | Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography. World Journal of Nuclear Medicine, 2020, 19, 432-434.  | 0.5 | 5         |
| 31 | Rare presentation of metastatic endometrioid adenocarcinoma of uterus mimicking as second primary in urinary bladder on <sup>18</sup> F-fluorodeoxyglucose positron-emission tomography/computed tomography. Indian Journal of Nuclear Medicine, 2019, 34, 169. | 0.3 | 0         |
| 32 | Krukenburg tumors arising from rare primary sites: Role of <sup>18</sup> F-fluorodeoxyglucose-positron emission tomography/computed tomography in management and outcome. Indian Journal of Nuclear Medicine, 2019, 34, 302.                                    | 0.3 | 2         |
| 33 | Expertise and Competence. , 2020, , 41-57.  |     | 0         |
| 34 | Uterine Uptake of 68Ga-FAPI-04 in Uterine Pathology and Physiology. Clinical Nuclear Medicine, 2022, 47, 7-13.  | 1.3 | 20        |
| 35 | F-18 FDG PET/CT Imaging in Normal Variants, Pitfalls and Artifacts in the Abdomen and Pelvis. Frontiers in Nuclear Medicine, 2022, 1, .   | 1.2 | 2         |
| 37 | Incidental Finding of Testicular Seminoma by 18F-Choline PET/CT in a Prostate Cancer Patient. Clinical Nuclear Medicine, 2022, 47, e249-e251.   | 1.3 | 1         |
| 38 | Dynamic whole-body FDG-PET imaging for oncology studies. Clinical and Translational Imaging, 2022, 10, 249-258.   | 2.1 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 39 | Increased Uptake of 18F-PSMA-1007 in Corpus Luteum Demonstrated by PET/CT. Clinical Nuclear Medicine, 2022, 47, e331-e332.   | 1.3 | 3         |
| 40 | A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies. Cancers, 2022, 14, 1779.   | 3.7 | 7         |
| 41 | Heart and bladder detection and segmentation on FDG PET/CT by deep learning. BMC Medical Imaging, 2022, 22, 58.  | 2.7 | 2         |
| 42 | Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3571-3580.         | 6.4 | 12        |
| 43 | Things are because we see them (O. Wilde): new radiopharmaceuticals for nuclear medicine imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.   | 6.4 | 0         |
| 44 | Presentation, Management, and Outcome of Primary Leiomyosarcoma of the Spine: A Systematic Review. World Neurosurgery, 2022, 163, 25-35.   | 1.3 | 1         |
| 46 | PET-CT in Clinical Adult Oncologyâ€”IV. Gynecologic and Genitourinary Malignancies. Cancers, 2022, 14, 3000.   | 3.7 | 11        |
| 47 | Papillary thyroid cancer with suspicious uterine cervix metastasis: a case report and literature review. Gland Surgery, 2022, .  | 1.1 | 0         |
| 48 | Ovarian Fibroma Mimicking Malignant Tumor on F-18 FDG PET/CT. Medecine Nucleaire, 2022, 46, 198-200.   | 0.2 | 0         |
| 49 | Radiolabeled FAP inhibitors as new pantumoral radiopharmaceuticals for PET imaging: a pictorial essay. Clinical and Translational Imaging, 2023, 11, 95-106.   | 2.1 | 3         |
| 50 | Endometriumkarzinom. , 2022, , 668-686.  |     | 0         |
| 52 | Imaging in Gynaecological Malignancies. , 2022, , 47-67.   |     | 0         |
| 53 | Genitourinary imaging. , 2023, , 289-312.  |     | 1         |
| 54 | Hypermetabolic Subserosal Uterine Leiomyoma With Synchronous Atypical Multiple Myeloma Mimicking Ovarian Malignancy With Multiple Bone Metastases on 18F-FDG PET/CT. Clinical Nuclear Medicine, 2023, 48, 199-200. | 1.3 | 0         |
| 55 | Cervix Abscess Mimicking Cervical Cancer Explored With 18F-FDG PET/CT and MRI. Clinical Nuclear Medicine, 2023, 48, e237-e238.   | 1.3 | 3         |
| 58 | Carcinome du corps ut  rin. , 2022, , 646-661.   |     | 0         |
| 59 | Four-dimensional quantitative analysis using FDG-PET in clinical oncology. Japanese Journal of Radiology, 2023, 41, 831-842.   | 2.4 | 4         |
| 60 | Abdomen and pelvis. , 2023, , 157-339.   |     | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 61 | A Remarkable Difference in Pharmacokinetics of Fluorinated Versus Iodinated Photosensitizers Derived from Chlorophyll-a and a Direct Correlation between the Tumor Uptake and Anti-Cancer Activity. <i>Molecules</i> , 2023, 28, 3782.   | 3.8 | 2         |
| 62 | 18F-fluoro-2-deoxy-2-glucose PET/CT (FDG PET/CT) in staging of high-risk renal and urothelial bladder cancers (COPPER trial protocol. <i>BJUI Compass</i> , 0, , .   | 1.3 | 0         |
| 63 | Feasibility of quantitative diffusion-weighted imaging during intra-procedural MRI-guided brachytherapy of locally advanced cervical and vaginal cancers. <i>Brachytherapy</i> , 2023, 22, 736-745.  | 0.5 | 0         |
| 64 | The accuracy of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the detection of ovarian cancer relapse in patients with rising cancer antigen 125 (CA-125) levels. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2023, 54, . | 0.6 | 0         |
| 65 | 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature. <i>Journal of Imaging</i> , 2023, 9, 223.   | 3.0 | 2         |
| 66 | Clinical applications of fibroblast activation protein-targeted theranostics in oncologic and nononcologic disease: Current status and future directions. , 2023, 1, 340-361.  |     | 1         |
| 67 | Impact of the 2023 FIGO Staging System for Endometrial Cancer on the Use of Imaging Services: An Indian Perspective. <i>Indian Journal of Radiology and Imaging</i> , 0, , .   | 0.8 | 0         |
| 68 | Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review. <i>Seminars in Nuclear Medicine</i> , 2024, 54, 270-292.  | 4.6 | 1         |